Bionest

Success for Amylyx in ALS

We take a look at the approval of Relyvrio, the third approved treatment for ALS, and the first to show both a slowing of disease progression and extended survival.

Bionest

Highlights from AAN: Part 1

The Bionest team attended the American Academy of Neurology (AAN) in early May, where we heard exciting data presented in a number of neurological conditions. Among the highlights of this year’s conference:   Transformative Success in Spinal Muscular Atrophy   Spinal muscular atrophy (SMA) was a hot topic at AAN, with presentations of positive clinical...